Pheochromocytomas and Paragangliomas Market Summary

• According to DelveInsight’s analysis, the Pheochromocytoma and Paraganglioma market size was found to be approximately USD 300 million in the leading markets (the United States, the EU4 Germany, France, Italy, and Spain—the United Kingdom, and Japan) in 2026 and is expected to grow at a CAGR of 7.3% during the forecast period (2026-2036).
• The Pheochromocytoma and Paraganglioma Market companies developing therapies include - Novartis, Progenics Pharmaceuticals, Lantheus Holdings, Inc., Hikma Pharmaceuticals PLC, Pfizer Inc., Baxter International, ITM Isotope Technologies Munich SE, Curium Pharma, Siemens Medical Solutions USA, Inc, and others.

Pheochromocytoma and Paraganglioma Market and Epidemiology Analysis

• Approximately 10% of pheochromocytomas and 40% of paragangliomas are classified as malignant. Germline genetic mutations have been identified in roughly 30% of patients. Certain mutations, especially those affecting the SDHx genes, are associated with a higher probability of malignant transformation.
• The age-related rise in PCPG burden reflects the greater likelihood of tumor detection in middle-aged and older adults, driven by the cumulative impact of genetic susceptibility, prolonged exposure to physiological stressors, and the increasing use of advanced diagnostic imaging. In addition, routine abdominal imaging and endocrine evaluations in older populations frequently identify adrenal incidentalomas, contributing to a higher concentration of diagnosed cases in later decades of life compared with younger age groups.
• Almost 75% of the PCPG cases are benign with surgery as the standard of care (SOC), whereas the remaining 25% are metastatic cases with surgery, radiation, chemotherapy, radioligand therapies along with targeted therapies (sunitinib, lenvatinib, pazopanib, everolimus, and sorafenib) as SOC.
• The introduction of WELIREG into the PCPG treatment landscape in 2026, represents a significant advance in a field with limited systemic options. By targeting the hypoxia-inducible factor (HIF) pathway, a key driver in many PCPG tumors, it introduces a mechanism-based therapeutic approach aligned with tumor biology. Its availability expands targeted treatment options, supports the shift toward precision oncology, and may stimulate further innovation and biomarker-driven strategies in the PCPG therapeutic space.
• Pharmaceutical companies developing therapies to treat PCPG include: Perspective Therapeutics (VMT-a-NET), Novartis (LUTATHERA/Lutetium [177Lu], Jazz Pharmaceuticals (ONC206/JZP3507), and Nxera Pharma (HTL0039732).
• Limited sensitivity of current biomarkers and histopathology to detect small lesions or predict metastatic potential in PCPG necessitates prolonged monitoring and highlights the need for reliable predictive biomarkers to improve risk stratification and guide treatment decisions.

Factors Affecting the Pheochromocytoma and Paraganglioma Market Growth

Rising Disease Incidence and Improved Diagnosis

The increasing incidence of rare neuroendocrine tumors such as pheochromocytoma and paraganglioma is one of the major drivers of market growth. Improved diagnostic techniques, including advanced imaging technologies and genetic testing, have enhanced detection rates and increased the number of diagnosed cases. 

Advancements in Targeted Therapies and Precision Medicine

The emergence of targeted therapies has significantly transformed the treatment landscape. Novel approaches such as HIF-2α inhibitors, peptide receptor radionuclide therapy (PRRT), and radiopharmaceutical agents are being explored to improve patient outcomes. These innovations are expected to expand therapeutic options for advanced or metastatic PCPG, thereby boosting market growth.

Regulatory Approvals and Novel Drug Launches

Recent regulatory approvals are also accelerating market expansion. For example, the FDA approval of belzutifan (WELIREG) as an oral therapy for advanced pheochromocytoma and paraganglioma has introduced a new treatment option for patients with unresectable or metastatic disease. Such breakthroughs increase physician adoption and drive market uptake of new therapies.

Growing Clinical Pipeline and R&D Investments

The ‘Pheochromocytoma and Paraganglioma market is supported by a strong clinical pipeline with several investigational therapies under development by pharmaceutical and biotechnology companies. Continuous investments in oncology research and clinical trials are expected to bring innovative treatment modalities to market, further strengthening growth prospects.

Increasing Awareness and Genetic Screening Programs

Enhanced physician awareness and broader genetic screening programs are improving early detection and patient identification. Since PCPG is often associated with hereditary syndromes, wider adoption of genetic testing is increasing diagnosis rates and expanding the treatable patient population.

Request a sample to unlock the CAGR for "Pheochromocytoma and Paraganglioma Market Forecast."

DelveInsight's ‘Pheochromocytoma and Paraganglioma (PCPG) Market Insights, Epidemiology and Market Forecast 2036’ report delivers an in-depth understanding of the PCPG, historical and forecasted epidemiology, as well as the PCPG market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Pheochromocytoma and Paraganglioma (PCPG) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, PCPG patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2026-2036) across global regions. The report highlights key unmet medical needs in PCPG and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Pheochromocytoma and Paraganglioma Disease Understanding

Pheochromocytoma and Paraganglioma Overview

Pheochromocytoma and paraganglioma (PCPG) are rare neuroendocrine tumors that arise from chromaffin cells associated with the autonomic nervous system. Pheochromocytomas originate in the adrenal medulla, while paragangliomas develop outside the adrenal glands in sympathetic or parasympathetic ganglia. These tumors often produce excess catecholamines, leading to symptoms such as hypertension, headaches, palpitations, and sweating. Although many cases are benign, a proportion can become malignant or metastatic, making early detection and management crucial.

Pheochromocytoma and Paraganglioma Diagnosis

Diagnosis of Pheochromocytoma and Paraganglioma typically involves a combination of biochemical testing and imaging techniques. Initial evaluation often includes measurement of plasma-free or urinary fractionated metanephrines, which help detect excess catecholamine production. Once biochemical evidence is confirmed, imaging studies such as CT scans, MRI, or functional imaging like PET or MIBG scans are used to locate and characterize the tumors. Genetic testing is also recommended in many cases since a significant percentage of PCPG cases are associated with hereditary syndromes.

Pheochromocytoma and Paraganglioma Treatment

Treatment of pheochromocytoma and paraganglioma primarily depends on the tumor’s location, size, and whether it has spread. Surgical removal of the tumor remains the standard treatment for localized disease and often requires preoperative medical management with alpha- and beta-blockers to control blood pressure and prevent complications. In advanced or metastatic cases, treatment options may include radiopharmaceutical therapy, targeted therapies, chemotherapy, and supportive management to control symptoms. Emerging therapies and ongoing clinical research are expected to improve outcomes and expand treatment options for patients with PCPG.

Further details related to country-based variations are provided in the report.

Pheochromocytoma and Paraganglioma (PCPG) Epidemiology

Key Findings from PCPG Epidemiological Analysis and Forecast

• According to DelveInsight’s estimates, in 2025, the total number of incident cases of PCPG in the 7MM were ~4,900.
• In the US, germline or somatic mutations accounted for ~1,800 cases in 2025, while the ~600 cases were associated with tumors with no genetic alterations.
• In Japan, the highest number of age-specific incident PCPG cases in 2025 was observed in the 50–74 years age group (~340 cases), while individuals aged under 25 years accounted for the lowest number of cases (~46).
• In the US, localized PCPG accounted for the majority of diagnoses compared with metastatic disease, reflecting the tendency for most tumors to be detected before distant spread, although all PCPGs retain metastatic potential.

Pheochromocytoma and Paraganglioma Market Recent Developments and Breakthroughs

• As of January 2026, LUTATHERA’s US orphan drug exclusivity has expired, but formulation patents remain valid until 2039 (including pediatric exclusivity) and are currently under challenge by generic applicants. In the EU, its primary patent protection is expected to expire in 2029.
• In January 2026, Perspective Therapeutics presented updated interim results from its ongoing Phase I/II trial evaluating [212Pb]VMT-a-NET in patients with unresectable or metastatic SSTR2-expressing NETs as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI).
• In June 2025, Perspective Therapeutics aligned with the US FDA to open Cohort 3 in its Phase I/IIa trial of [212Pb]VMT-a-NET for patients with unresectable or metastatic SSTR2-positive NETs who have not previously received radiopharmaceutical therapy.

Pheochromocytoma and Paraganglioma (PCPG) Drug Analysis

The Pheochromocytoma and Paraganglioma drug chapter provides a detailed, market-focused review of approved therapies and the Pheochromocytoma and Paraganglioma emerging pipeline across Phase I/II–II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the PCPG treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the PCPG therapeutics market.

Pheochromocytoma and Paraganglioma Marketed Drugs

Belzutifan (WELIREG): Merck

Belzutifan (WELIREG), developed by Merck, is a novel, potent, and selective inhibitor of HIF-2a. Initially it was approved for VHL disease–associated tumors and subsequently for RCC, its approval in May 2025 for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic PCPG represents a strategic expansion into a rare tumor indication.

Pheochromocytoma and Paraganglioma Emerging Drugs

Lutetium [177Lu] oxodotreotide/dotatate (LUTATHERA): Novartis

Lutetium [177Lu] oxodotreotide is a PRRT developed and marketed by Novartis. It comprises the somatostatin analogue dotatate radiolabeled with the beta-emitting isotope lutetium-177, enabling targeted delivery of ionizing radiation to tumor cells expressing somatostatin receptors (predominantly Subtype 2). As the PCPG cohort in the NETTER-P study was exploratory and Novartis has not disclosed further development plans for this indication. Therefore, DelveInsight assumes that Novartis may need to initiate a dedicated registrational trial in PCPG. If initiated soon, considering ~2.5–3 years for trial completion and ~1 year for approval, the potential launch could occur around 2031.

Pheochromocytoma and Paraganglioma (PCPG) Market Outlook

The PCPG market is undergoing a gradual transformation after decades of relying mainly on surgery, symptomatic management, and limited systemic therapies such as chemotherapy and radionuclide treatments. Recent advances in precision oncology have begun to reshape the landscape, highlighted by the FDA approval of belzutifan (WELIREG) in May 2025, the first oral targeted therapy for patients with locally advanced, unresectable, or metastatic PCPG. This milestone validates HIF-2a inhibition as a therapeutic strategy and establishes a regulatory precedent for targeted treatments in this rare neuroendocrine tumor segment.

Alongside this approval, emerging modalities such as radiopharmaceutical therapies (e.g., 131I-MIBG and PRRT with 177Lu-DOTATATE) and investigational radioligand approaches are expanding treatment options for advanced disease. Meanwhile, pipeline candidates including novel radioligands, targeted inhibitors, and combination approaches are progressing through clinical development, indicating that the PCPG treatment paradigm is gradually shifting toward mechanism-driven and precision-based therapies, similar to the evolution seen in other rare oncology markets.

Key Findings from Spinal Cord Injury Market Forecast Report

• Among the 7MM, the US accounted for the largest market size of PCPG. i.e., USD ~200 million in 2025
• In 2036, among all the therapies for PCPG, the highest revenue is estimated to be generated by belzutifan (WELIREG), in the US.
• The entry of mid-stage candidates such as JZP3507 (ONC206) is expected to intensify competition in the PCPG treatment landscape during the latter half of the forecast period.

Pheochromocytoma and Paraganglioma Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Pheochromocytoma and Paraganglioma market or expected to get launched during the study period 2020–2034. The analysis covers Pheochromocytoma and Paraganglioma market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and allows comparison of the drugs based on market share and size. This analysis is useful in identifying factors influencing market uptake and supporting financial and regulatory decision-making.

Pheochromocytoma and Paraganglioma Clinical Trials Activities

The Pheochromocytoma and Paraganglioma pipeline report provides insights into clinical trials in Phase II and Phase III stages. It also analyzes the key players involved in developing targeted therapeutics for Pheochromocytoma and Paraganglioma.

Pheochromocytoma and Paraganglioma Pipeline Development Activities

The Pheochromocytoma and Paraganglioma clinical trial analysis report covers detailed information on collaborations, acquisitions and mergers, licensing activities, patent details, and other strategic developments related to emerging therapies in the Pheochromocytoma and Paraganglioma market.

Detailed insights of emerging therapies' drug uptake is included in the report

Pheochromocytoma and Paraganglioma Market Access and Reimbursement

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The United States

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Industry Experts and Physician Views for Pheochromocytoma and Paraganglioma (PCPG)

To keep up with PCPG market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the PCPG emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in PCPG, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights at country level. Centers such as the Cancer Research Institute at Beth Israel Deaconess Medical Center, University of Würzburg, and Cardiovascular Prevention Institute, etc. were contacted.Their opinion helps understand and validate current and emerging PCPG therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in PCPG.

Pheochromocytoma and Paraganglioma Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of PCPG, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Pheochromocytoma and Paraganglioma Market Report

• The Pheochromocytoma and Paraganglioma Market report covers a segment of key events, an executive summary, a descriptive overview of PCPG, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the PCPG market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM PCPG market.

Pheochromocytoma and Paraganglioma Market Report Insights

• Pheochromocytoma and Paraganglioma (PCPG) Patient Population Forecast
• Pheochromocytoma and Paraganglioma (PCPG) Therapeutics Market Size
• Pheochromocytoma and Paraganglioma (PCPG) Pipeline Analysis
• Pheochromocytoma and Paraganglioma (PCPG) Market Size and Trends
• Pheochromocytoma and Paraganglioma (PCPG) Market Opportunity (Current and forecasted)

Pheochromocytoma and Paraganglioma Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Pheochromocytoma and Paraganglioma Market Market Research Report
• 11-Year Forecast
• Pheochromocytoma and Paraganglioma (PCPG) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Pheochromocytoma and Paraganglioma (PCPG) Treatment Addressable Market (TAM)
• Pheochromocytoma and Paraganglioma (PCPG) Competitve Landscape
• Pheochromocytoma and Paraganglioma (PCPG)) Major Companies Insights
• Pheochromocytoma and Paraganglioma (PCPG) Price Trends and Analogue Assessment
• Pheochromocytoma and Paraganglioma (PCPG) Therapies Drug Adoption/Uptake
• Pheochromocytoma and Paraganglioma (PCPG) Therapies Peak Patient Share Analysis

Pheochromocytoma and Paraganglioma Market Report Assessment

• Pheochromocytoma and Paraganglioma (PCPG) Current Treatment Practices
• Pheochromocytoma and Paraganglioma (PCPG) Unmet Needs
• Pheochromocytoma and Paraganglioma (PCPG) Clinical Development Analysis
• Pheochromocytoma and Paraganglioma (PCPG) Emerging Drugs Product Profiles
• Pheochromocytoma and Paraganglioma (PCPG) Market attractiveness
• Pheochromocytoma and Paraganglioma (PCPG) Qualitative Analysis (SWOT and conjoint analysis)

Pheochromocytoma and Paraganglioma Market FAQs

Pheochromocytoma and Paraganglioma Market Market Insights

• What was the Pheochromocytoma and Paraganglioma Market market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of PCPG?
• What are the disease risks, burdens, and unmet needs of PCPG? What will be the growth opportunities across the 7MM concerning the patient population with PCPG?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of PCPG? What are the current guidelines for treating PCPG in the US, Europe, and Japan?

Reasons to Buy the Pheochromocytoma and Paraganglioma Market Forecast Report

• The Pheochromocytoma and Paraganglioma Market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the PCPG market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.